FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950776331> ?p ?o ?g. }

• W2950776331 endingPage "1066" @default.
• W2950776331 startingPage "1065" @default.
• W2950776331 abstract "Background: The thalassemias are a group of disorders in which mutation (s) in the α- and/or β-globin locus lead to an imbalance between α- and β-globin production. The disease is characterized by the precipitation of excess α- or β-globin, ineffective erythropoiesis, and peripheral hemolysis, with resultant anemia. Energy supply in the form of ATP appears to be insufficient in thalassemic red blood cells (RBCs) to maintain RBC membrane fitness and clearance of globin precipitates. Mitapivat (AG-348) is an oral, small-molecule, allosteric activator of the RBC-specific form of pyruvate kinase (PK-R). In healthy adults, mitapivat activates wild-type PK-R and increases ATP levels in RBCs. In adults with a mutant PK-R and non–transfusion-dependent anemia due to pyruvate kinase deficiency (NCT02476916), oral mitapivat was well tolerated and induced rapid, durable hemoglobin (Hb) increases. In β-thalassemic mice, mitapivat increases ATP levels, reduces ineffective erythropoiesis, and improves anemia, RBC survival, and indices of iron overload. These data support the hypothesis that increased ATP synthesis mediated via the activation of PK-R by mitapivat may improve the survival of thalassemic RBCs in the bone marrow and/or peripheral circulation. A phase 2 study of mitapivat is ongoing to further inform this hypothesis. Aims: To report the design of the ongoing phase 2 study of mitapivat in adults with non–transfusion-dependent thalassemia (NTDT). Methods: This phase 2, multicenter, open-label study (NCT03692052) is evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of mitapivat in adults with NTDT. It consists of a 24-week core period followed by a 2-year extension period (Figure). Approximately 17 subjects with NTDT will be enrolled, including a minimum of 8 subjects with β-thalassemia. All eligible subjects will receive an initial mitapivat dose of 50 mg orally twice daily (BID). At the Week 6 visit the dose may be increased to 100 mg orally BID, depending on safety and Hb response. Key inclusion criteria are: 1) β-thalassemia (with or without α-globin gene mutation), Hb E/β-thalassemia or Hb H disease; 2) baseline Hb ≤9 g/dL; 3) NTDT defined as ≤5 units of RBCs transfused in the preceding 24 weeks and no transfusions in the 8 weeks prior to the first day of study drug); 4) adequate organ function. The primary endpoint is the proportion of subjects who achieve an Hb response, defined as an increase in Hb of ≥1.0 g/dL from baseline at any time between Week 4 and Week 12 (inclusive). Key secondary endpoints include changes in Hb and markers of hemolysis and hematopoietic activity, and assessments of safety and pharmacokinetics. The study is currently enrolling. Results: Not yet available.Summary/Conclusion: This is the first study of mitapivat in subjects with NTDT. The study will provide insights into the efficacy, safety, and pharmacokinetics of PK-R activation in NTDT. Mitapivat may represent a novel therapeutic approach in the management of anemia in thalassemic syndromes." @default.
• W2950776331 created "2019-06-27" @default.
• W2950776331 creator A5001225225 @default.
• W2950776331 creator A5038263967 @default.
• W2950776331 creator A5042570424 @default.
• W2950776331 creator A5047420828 @default.
• W2950776331 creator A5054028071 @default.
• W2950776331 creator A5068187065 @default.
• W2950776331 date "2019-06-01" @default.
• W2950776331 modified "2023-09-27" @default.
• W2950776331 title "PB2396 DESIGN OF A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF MITAPIVAT (AG-348) IN ADULTS WITH NON–TRANSFUSION-DEPENDENT THALASSEMIA" @default.
• W2950776331 doi "https://doi.org/10.1097/01.hs9.0000568048.64959.4b" @default.
• W2950776331 hasPublicationYear "2019" @default.
• W2950776331 type Work @default.
• W2950776331 sameAs 2950776331 @default.
• W2950776331 citedByCount "0" @default.
• W2950776331 crossrefType "journal-article" @default.
• W2950776331 hasAuthorship W2950776331A5001225225 @default.
• W2950776331 hasAuthorship W2950776331A5038263967 @default.
• W2950776331 hasAuthorship W2950776331A5042570424 @default.
• W2950776331 hasAuthorship W2950776331A5047420828 @default.
• W2950776331 hasAuthorship W2950776331A5054028071 @default.
• W2950776331 hasAuthorship W2950776331A5068187065 @default.
• W2950776331 hasBestOaLocation W29507763311 @default.
• W2950776331 hasConcept C126322002 @default.
• W2950776331 hasConcept C134018914 @default.
• W2950776331 hasConcept C20251656 @default.
• W2950776331 hasConcept C203014093 @default.
• W2950776331 hasConcept C2777799968 @default.
• W2950776331 hasConcept C2778248108 @default.
• W2950776331 hasConcept C2779703530 @default.
• W2950776331 hasConcept C2779902561 @default.
• W2950776331 hasConcept C2780644154 @default.
• W2950776331 hasConcept C2780844101 @default.
• W2950776331 hasConcept C2780854706 @default.
• W2950776331 hasConcept C62231903 @default.
• W2950776331 hasConcept C71924100 @default.
• W2950776331 hasConcept C98274493 @default.
• W2950776331 hasConceptScore W2950776331C126322002 @default.
• W2950776331 hasConceptScore W2950776331C134018914 @default.
• W2950776331 hasConceptScore W2950776331C20251656 @default.
• W2950776331 hasConceptScore W2950776331C203014093 @default.
• W2950776331 hasConceptScore W2950776331C2777799968 @default.
• W2950776331 hasConceptScore W2950776331C2778248108 @default.
• W2950776331 hasConceptScore W2950776331C2779703530 @default.
• W2950776331 hasConceptScore W2950776331C2779902561 @default.
• W2950776331 hasConceptScore W2950776331C2780644154 @default.
• W2950776331 hasConceptScore W2950776331C2780844101 @default.
• W2950776331 hasConceptScore W2950776331C2780854706 @default.
• W2950776331 hasConceptScore W2950776331C62231903 @default.
• W2950776331 hasConceptScore W2950776331C71924100 @default.
• W2950776331 hasConceptScore W2950776331C98274493 @default.
• W2950776331 hasIssue "S1" @default.
• W2950776331 hasLocation W29507763311 @default.
• W2950776331 hasLocation W29507763312 @default.
• W2950776331 hasOpenAccess W2950776331 @default.
• W2950776331 hasPrimaryLocation W29507763311 @default.
• W2950776331 hasRelatedWork W2418080073 @default.
• W2950776331 hasRelatedWork W2808641093 @default.
• W2950776331 hasRelatedWork W2986356818 @default.
• W2950776331 hasRelatedWork W3213587857 @default.
• W2950776331 hasRelatedWork W3214617383 @default.
• W2950776331 hasRelatedWork W4210811183 @default.
• W2950776331 hasRelatedWork W4283370847 @default.
• W2950776331 hasRelatedWork W4283380745 @default.
• W2950776331 hasRelatedWork W4310103562 @default.
• W2950776331 hasRelatedWork W4322495009 @default.
• W2950776331 hasVolume "3" @default.
• W2950776331 isParatext "false" @default.
• W2950776331 isRetracted "false" @default.
• W2950776331 magId "2950776331" @default.
• W2950776331 workType "article" @default.